Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by an immunosuppressive milieu in the tumour microenvironment (TME) that fosters disease growth and therapeutic resistance. Hypomethylating agents (HMAs) demonstrate clinical efficacy in AML patients and exert immunomodulatory activities. In the present study, we show that guadecitabine augments both antigen processing and presentation, resulting in increased AML susceptibility to T cell-mediated killing. Exposure to HMA results in the activation of the endogenous retroviral pathway with concomitant downstream amplification of critical mediators of inflammation. In an immunocompetent murine leukaemia model, guadecitabine negatively regulates inhibitory accessory cells in the TME by decreasing PD-1 (also termed PDCD1) expressing T cells and reducing AML-mediated expansion of myeloid-derived suppressor cells. Therapy with guadecitabine results in enhanced leukaemia-specific immunity, as manifested by increased CD4 and CD8 cells targeting syngeneic leukaemia cells. We have previously reported that vaccination with AML/dendritic cell fusions elicits the expansion of leukaemia-specific T cells and protects against disease relapse. In the present study, we demonstrate that vaccination in conjunction with HMA therapy results in enhanced anti-leukaemia immunity and survival. The combination of a novel personalized dendritic cell/AML fusion vaccine and an HMA has therapeutic potential, and a clinical trial investigating this combination is planned.
Summary
Acute myeloid leukaemia (AML) is a lethal haematological malignancy characterized by an immunosuppressive milieu in the tumour microenvironment (TME) that fosters disease growth and therapeutic resistance. Hypomethylating agents (HMAs) demonstrate clinical efficacy in AML patients and exert immunomodulatory activities. In the present study, we show that guadecitabine augments both antigen processing and presentation, resulting in increased AML susceptibility to T cell-mediated killing. Exposure to HMA results in the activation of the endogenous retroviral pathway with concomitant downstream amplification of critical mediators of inflammation. In an immunocompetent murine leukaemia model, guadecitabine negatively regulates inhibitory accessory cells in the TME by decreasing PD-1 (also termed PDCD1) expressing T cells and reducing AML-mediated expansion of myeloid-derived suppressor cells. Therapy with guadecitabine results in enhanced leukaemia-specific immunity, as manifested by increased CD4 and CD8 cells targeting syngeneic leukaemia cells. We have previously reported that vaccination with AML/dendritic cell fusions elicits the expansion of leukaemia-specific T cells and protects against disease relapse. In the present study, we demonstrate that vaccination in conjunction with HMA therapy results in enhanced anti-leukaemia immunity and survival. The combination of a novel personalized dendritic cell/AML fusion vaccine and an HMA has therapeutic potential, and a clinical trial investigating this combination is planned.
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Acute myeloid leukaemia (AML) is a lethal haematological malignancy (Derolf et al, 2009; D€ ohner et al, 2010) . Standard therapy is often inadequate in sustaining durable remissions due to the emergence of chemotherapy-resistant clones (Ding et al, 2012) . AML is characterized by an immunosuppressive tumour microenvironment (TME) that promotes immune tolerance and disease escape (Isidori et al, 2014; Coles et al, 2015; Austin et al, 2016) . A major area of investigation is the development of immunotherapeutic strategies that enhance the targeting of AML by immune effector cells and the development of memory responses that protect from subsequent relapse (Beyar-Katz & Gill, 2018) . The unique potency of cellular immunity in targeting AML is highlighted by the observation that allogeneic stem cell transplantation (alloSCT) is curative for a subset of patients due to the targeting of leukaemic cells by alloreactive lymphocytes. However, due to the lack of donor lymphocyte specificity for malignant cells, morbid sequelae of alloSCT includes graftversus-host-disease and opportunistic infections (Copelan, 2006) . Developing effective leukaemia-specific immunotherapies is further impeded by the immunosuppressive milieu, including impaired antigen presentation, increased regulatory T-cells, dysregulation of checkpoint pathways, and an increased burden of myeloid-derived suppressor cells (MDSCs) (Andersen, 2014; Isidori et al, 2014; Schl€ oßer et al, 2014; Sharma & Allison, 2015) . In contrast, therapeutic agents with immunomodulatory properties can potentially overcome immune tolerance, enhance tumour immunogenicity, and induce the expansion of functionally competent leukaemia-specific T cells (Lichtenegger et al, 2015) .
Hypomethylating agents (HMAs) demonstrate potent antileukaemia effects with the capacity to induce disease remission in a subset of AML patients (L€ ubbert et al, 2011; Kantarjian et al, 2012; Ritchie et al, 2013) . While the mechanism of action of HMAs in AML is diverse, there is increasing appreciation of immunomodulatory effects in mediating response. In solid tumour models, HMAs exert regulatory effects on the antigen presenting properties of malignant cells (Karpf, 2006; Woloszynska-Read et al, 2008; Akers et al, 2010; Almstedt et al, 2010; Goodyear et al, 2010; Srivastava et al, 2014; Ørs-kov et al, 2015) . Pre-treatment of tumour cells with HMAs primes tumours to induce potent immune responses. Azacitidine exposure yielded an enhanced response to checkpoint antibody therapy in a lung cancer model (Juergens et al, 2011) . Moreover, HMA treatment accentuated responses to anti-CTLA4 immunotherapy in a melanoma model through activation of the endogenous retroviral pathway (ERV) (Chiappinelli et al, 2015) . The ERV pathway is an evolutionary conserved pathway that, when stimulated, culminates in T-cell activation through interferon (IFN) production (Stoye, 2012) . In addition, HMAs potentially impact functional properties of accessory and immune effector cells that populate the TME and mediate tumour-associated immune suppression.
In the present study, we characterize the immunoregulatory effects of the second generation HMA, guadecitabine (SGI-110), on antigen presentation by leukaemia cells, recruitment of MDSCs, and expansion of functionally-competent leukaemia-specific T cells. We demonstrate that HMA enhances presentation of the leukaemia antigen, PR-1, associated with increased expression of the antigen processing enzyme, TAP2. Treatment with SGI-110 in an immunocompetent murine leukaemia model decreases infiltrating PD-1 (also termed PDCD1) expressing T cells and MDSCs at the tumour site resulting in increased levels of functionally-active leukaemiaspecific T cells. Immunoregulatory effects of HMA are associated with the signalling via the ERV pathway providing a pro-inflammatory environment promoting T cell activation.
We have developed a personalized tumour vaccine in which patient-derived tumour cells are fused with autologous dendritic cells (DCs) such that a broad array of tumour antigens are presented in the context of DC-mediated co-stimulation (Rosenblatt et al, 2005; Rosenblatt & Avigan, 2006) . In a phase I/II clinical trial of 17 AML patients achieving a chemotherapy-induced remission, vaccination resulted in the durable expansion of leukaemia-specific T cells. Despite a median age of 63 years, 71% of patients remained alive without disease recurrence at a 57-month median follow-up (Rosenblatt et al, 2016) . Despite these encouraging results, vaccine durability remains uncertain as responses may diminish over time due to immune tolerance. We hypothesized that HMA therapy would enhance response to vaccination by increasing the immunogenicity of the leukaemia cell target and altering the immunosuppressive milieu of the TME. In a murine leukaemia model, we observed that vaccination in conjunction with SGI-110 results in increased expansion of leukaemia-specific T cells and improved survival in mice treated with SGI-110 plus the fusion vaccine as compared to mice treated with either agent alone.
Methods

Cell culture
The AML cells lines THP-1, MV4-11, MOLM-14 (human) and TIB-49 (murine) were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA), cultured at 37°C in a humidified 5% CO 2 incubator and maintained in RPMI 1640 media (Cellgro, Manassas, VA, USA) supplemented with heat-inactivated 10% fetal calf serum albumin (Sigma-Aldrich, St. Louis, MO, USA) and 100 iu/ml penicillin, 100 lg/ml streptomycin (Cellgro). Primary human AML cells were cultured similarly in a concentration of 1 million cells per ml.
Flow cytometry
Cells were analysed for green fluorescent protein (GFP), PD-1, CD11b, and Gr1 expression by multichannel flow cytometry. Cells were incubated with FcR blocking reagent (Miltenyi, Bergisch Gladbach, Germany) for 10 min at room temperature. Subsequently, cells were incubated with the anti-PD-1-allophycocyanin (APC) (eBioscience, San Diego, CA, USA), antiCD11b-APC-cyanin 7 (Cy7) (BioLegend, San Diego, CA, USA) and anti-Gr1-phycoerythrin (PE) (BioLegend) or isotype control. The cells were analyzed using FACS Aria (BD Biosciences, San Jose, CA, USA). Kaluza software (Beckman Coulter, Brea, CA) was used to analyse the obtained data.
The expression of c-interferon (IFN-c) was analysed by intracellular flow cytometry. Cells were pulsed with GolgiStop (1 lg/ml; BD Pharmingen, Franklin Lakes, NJ, USA) for 4-6 h at 37°C before analysis. Cells were next harvested and labelled with CD4-pacific blue (PB) and CD8-fluorescein thiocyanate (FITC). Cells were then permeabilized by incubation in Cyto-fix/Cytoperm plus (BD Pharmingen) containing formaldehyde and saponin for 30 min at 4°C, washed twice in Perm/Wash solution, and incubated with PE-conjugated IFN-c (Invitrogen, Camarillo, CA, USA), or a matched isotype control for 30 min. Cells were washed in 1 9 Perm/ Wash solution prior to analysis.
T-cell receptor-like (TCRL) antibody assessment
The HLA-A2 positive cell line, THP-1, was treated with SGI-110 1 lmol/L twice daily for 2 days. The cells were analysed for PR-1 presentation using a TCRL antibody (8F4 monoclonal antibody, mAb) as described (Sergeeva et al, 2011) . HLA-A2 expression was assessed with the anti-HLA-A2 mAb, BB7.2.
Immunohistochemistry
AML cells were obtained from the bone marrow (BM) of patients with disease. Cytospins were prepared after isolation using anti-CD34 magnetic beads. Cells were stained with anti-TAP2 (Novus Biologicals, Centennial, CO, USA) or goat-anti-mouse IgG using the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA). Cells were fixed in 2% paraformaldehyde (Sigma-Aldrich) and visualized by phase contrast light microscopy (AX70 microscope; Olympus, Waltham, MA, USA) using an oil immersion objective lens (1009).
Western blot
MOLM-14 and MV4-11 were treated with low-dose decitabine (25 and 50 nmol/L) daily for 3 days. Cells were assessed for expression of ERV-3 (anti-ERV-3 Everest Biotech, Oxfordshire, UK, 30 kD) and IFNb (anti-IFNb Abcam, Cambridge, UK, 22 kD).
Leukaemia-specific immunity
Autologous DC/AML fusions were generated. Leukaemia cells were obtained from BM aspirates from AML patients with active disease and cryopreserved as per an Institutional Review Board (IRB)-approved protocol. Peripheral blood (PB) samples were subsequently obtained from patients achieving complete remission and peripheral blood monoclonal cells (PBMCs) were isolated via Ficoll density centrifugation. DCs were generated from adherent mononuclear cells cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 4 (IL-4) and tumour necrosis factor-alpha. DC and AML cells were fused by co-culture with polyethylene glycol (PEG). Fusions were cultured at a 1:10 ratio with autologous T cells for 6 days with 1 lmol/L SGI-110 or with diluent control. CD4 + and CD8 + populations expressing IFN-c production following stimulation with the vaccine were quantified. To assess for cytolytic capacity, autologous patient-derived T cells were cultured with fusions for 5-7 days. Fusion-stimulated T cells were assessed for their capacity to lyse leukaemia cells using a cytotoxic T lymphocyte (CTL) assay.
CTL assay
Fusion cells were generated as described above. Autologous T cells were stimulated with the fusion vaccine for 6 days. Vaccine-stimulated T cells were co-cultured with control autologous AML blasts or AML blasts exposed to twice daily treatment with 1 lmol/L SGI-110 for 2 days and left in culture for an additional 2 days. The lysis of AML blasts, with and without SGI-110, by vaccine-stimulated T cells was detected using a CTL flourochrome assay (OncoImmunin Inc., Gaithersburg, MD, USA). Target AML cells were incubated in APC-labelled phosphate-buffered saline (PBS) (1 ll of reconstituted TFL4 in PBS at 1:3000 ratio) at 1 9 10 6 cells/ml for 30 min at 37°C. Labelled cells were washed twice in PBS. Using SGI-110 treated or control human AML cells obtained through an IRB-approved protocol, autologous PBMCs were co-incubated with labelled target cells in the presence of a fluorogenic granzyme B substrate for 1-2 h at 37°C. Cells were washed and analysed by flow cytometry. Dead target cells were identified through dual staining for granzyme B and APC label. As a negative control, granzyme B positive tumour cells not co-cultured with T cells were quantified.
TME and leukaemia-specific immunity in-vivo C57BL/6J mice were inoculated with 1 9 10 5 GFP-transduced TIB-49 syngeneic AML cells via retro-orbital injection. Animals were treated with SGI-110 or diluent for 3 days, sacrificed on day 18 and assessed for tumour burden, MDSCs, and T cell PD-1 expression by flow cytometry. AML-specific T cells were quantified in BM and spleen by flow cytometry for intracellular IFN-c expression following exposure to TIB-49 lysate.
Synergy between fusions and HMA therapy in-vivo
Murine syngeneic DC/AML fusion cells were generated. DCs were generated from the BM mononuclear cells harvested from C57BL/6J mice cultured with IL-4 and GM-CSF for 5-7 days and fused with GFP+ syngeneic TIB-49 cells in the presence of PEG. Fusion cells were isolated by flow cytometric sorting for cells co-expressing CD86/GFP. C57BL/6J mice were retro-orbitally inoculated with 50 9 10 3 GFP-transduced syngeneic TIB-49 cells. Fig 1A) . We subsequently examined the impact of HMA exposure on presentation of the leukaemia-associated antigen using a T-cell receptor mimic antibody (8F4) that recognizes the PR-1-MHC-HLA-A2.1 complex on the surface of leukaemic cells where PR-1 is a known leukaemia-associated antigen (Sergeeva et al, 2011) . Exposure to SGI-110 resulted in an increase in PR-1 presentation (Fig 1B) as measured by flow cytometric analysis in THP-1 cells (n = 4; P < 0Á05). Of note, treatment of patient-derived AML cells with SGI-110 led to increase in TAP2 expression (8-75%) ( Fig 1C) . In contrast, co-stimulatory molecules expression of HLA-DR, CD80 and CD86 on patient-derived AML cells following exposure to SGI-110 was not altered ( Figure S1A ). Furthermore, the cytokine profile of AML cells was not affected following SGI-110 treatment ( Figure S1B ).
We subsequently examined the effect of SGI-110 on the TME in an immunocompetent murine model. C57BL/6J mice were retro-orbitally inoculated with 100 000 syngeneic TIB-49 cells stably transduced with GFP. Following establishment of disease as determined by the presence of AML cells in the peripheral blood (PB) on day 12, mice were treated with SGI-110 (1 mg/kg) or vehicle daily for 3 days. Prior dose escalation, in-vivo experiments were conducted to select appropriate SGI-110 dosing in our model. We aimed to select a dose that would preserve leukaemic engraftment in order to best study the immune effects of SGI-110 on the AML cell. To this end, there was no significant difference in the engraftment of GFP + TIB-49 cells in the spleens and BM between the SGI-110 (1 mg/kg) treated and control animals (Fig 2A) . However, exposure to SGI-110 resulted in a significant decrease in T cells expressing PD-1 levels among CD4 + splenocytes, as detected by flow cytometric analysis, with mean values 6Á3% and 3Á1% of vehicle control and SGI-110-treated mice, respectively (n = 4; P = 0Á01) (Fig 2B) . Furthermore, a statistically significant decrease in the number of MDSCs as measured by quantification of CD11b was observed in both the BM (n = 5; P = 0Á01) and spleens (n = 4; P = 0Á03) of SGI-110-treated mice, as compared to vehicle (Fig 2C) . We subsequently examined whether the effect of SGI-110 on the immunogenicity of AML cells and the microenvironment results in enhanced recognition of leukaemia cells by the native T-cell repertoire in the immunocompetent murine leukaemia model. Treatment with SGI-110 resulted in higher levels of CD4 and CD8 splenocytes expressing IFN-c upon exposure to syngeneic TIB-49 lysate (Fig 2D) .
Exposure to HMAs activates the endogenous retroviral pathway
HMAs induce a pro-inflammatory state via the activation of native ERV pathways. Activation of the ERV pathway results in enhanced IFNß expression leading to increased MHC HLA Class I expression and subsequently, immune stimulation in a solid tumour model (Chiappinelli et al, 2015) . In the present study, MOLM-14 and MV4-11 AML cell lines were cocultured in-vitro with decitabine (DAC) at 25 and 50 nmol/L for 3 days and analysed for ERV-3 expression by Western blotting. The results demonstrate significant up-regulation of ERV-3 expression after treatment with 50 nmol/L DAC (Fig 3A, B) . Due to activation of the ERV pathway, we examined the expression of IFNb following HMA treatment. Indeed, IFNb expression was shown to be upregulated following treatment (Fig 3A, B) .
In-vitro stimulation of PBMCs with a fusion vaccine plus HMA increases tumour-specific T cells and tumourspecific cytolytic capacity in AML patients
We have developed a personalized leukaemia vaccine that demonstrates the potent capacity to expand leukaemia-specific T cells and protection from relapse (Rosenblatt et al, 2016) . Given its effect on antigen presentation and the leukaemia-associated microenvironment, we postulated that HMA therapy would demonstrate synergy with the vaccine in generating protective leukaemia-specific immunity. To interrogate this hypothesis, fusion cells were generated from patient-derived leukaemic cells fused with autologous DCs and cultured at a 1:10 ratio with autologous T cells for 6 days in the presence and absence of 1 lmol/L SGI-110. Exposure to SGI-110 resulted in increased CD4 + population expressing IFN-c following stimulation with the vaccine (n = 4; P < 0Á05) (Fig 4A, B) . Given our finding that exposure to HMAs resulted in enhanced presentation of leukaemia-associated antigens, we hypothesized that in-vitro exposure to SGI-110 would augment the targeting of AML cells by vaccine-stimulated T
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Fig 2. SGI-110 alters the tumour microenvironment and enhances leukaemia-specific immunity. C57BL/6J mice were retro-orbitally inoculated with 100 000 syngeneic TIB-49 AML cells that were stably transduced with green fluorescent protein (GFP). The mice were then treated with 1 mg/kg SGI-110 or diluent control. At day 12 following inoculation, bone marrow (BM) and spleen cells were isolated and evaluated using flow cytometric analysis for (A) BM engraftment, (B) PD-1 expression of CD4 + cells in the spleen, (C) Myeloid-derived suppressor cell (MDSC) burden in the bone marrow and spleen, and (D) intracellular IFN-c expression after exposure to autologous tumour lysate in the bone marrow and spleen. cells. Autologous patient-derived T cells were cultured with fusions for 5-7 days. Fusion-stimulated T cells were assessed for their capacity to lyse leukaemia cells in a standardized flourochrome cytotoxic T lymphocyte (CTL) assay. First, autologous AML cells were exposed to 4 doses of 1 lM SGI-110 or diluent and then incubated for an additional 2 days. Results show that lysis of leukaemia cells by resting T cells and vaccine-stimulated T cells is augmented by pre-incubation of the AML cells with SGI-110 (n = 4; P < 0Á05) (Fig 4C, D) .
Vaccination with DC/AML fusions induces tumourspecific immunity and prevents leukaemia engraftment in an immunocompetent murine leukaemia model
We subsequently examined whether the combination of HMAs and the fusion vaccine would result in enhanced leukaemia-specific immunity and effective targeting of AML cells in-vivo in an immunocompetent syngeneic murine model. Fusion cells were generated as discussed in the methods section. Fusion cells were identified through sorting by coexpression of CD86 and GFP. Black mice were inoculated retro-orbitally with 150 9 10 3 GFP + TIB-49 cells and 24 h later, mice were injected subcutaneously with 100 9 10 3 sorted fusion cells. Two weeks following inoculation with TIB-49 cells, control mice exhibited significant tumour growth at the injection site as opposed to vaccine-treated mice (Fig 5A) . The BM of the mice was harvested and examined for tumour infiltration using GFP expression. Whereas all mice in the non-vaccinated group showed BM AML involvement, the vaccinated mice did not demonstrate any BM-infiltrating blasts (Fig 5B; P < 0Á05) . Moreover, stimulation of these BM-derived cells with autologous tumour lysate led to an expansion in tumour-specific CD4 + T cells as detected by intracellular IFN-c expression (Fig 5C; P < 0Á05).
Vaccination with DC/AML fusions in combination with HMA increases survival and induction of tumour-specific immunity in an immunocompetent murine leukaemia model
We next studied whether treatment with HMA was associated with enhanced response to DC/AML fusion vaccination in the murine leukaemia model. C57BL/6J mice were inoculated retro-orbitally with GFP + TIB-49 cells on day 1. Mice were divided into 4 separate cohorts of 5 mice each. The 4 cohorts were as follows: (i) vehicle-treated mice; (ii) SGI-110 (1 mg/ kg) on days 6-10; (iii) vaccine alone on day 12; (iv) SGI-110 (1 mg/kg) on days 6-10 and vaccine on day 12. Untreated mice were used as an additional control. Vaccine was administered after the establishment of AML. The experimental schema is summarized in Fig 6A. To assess the induction of tumour-specific immune response, splenocytes were harvested from animals at the time of euthanasia. IFN-c expression by CD4 and CD8 cells was quantified following exposure to syngeneic tumour lysate. Splenocytes from healthy mice were used as baseline for IFN-c expression. Therapy with SGI-110 plus the vaccine showed a significant increase in tumour-specific T cells as detected by IFN-c production in CD4 and CD8 splenocytes, when compared to treatment with the fusion vaccine (n = 5; P = 0Á02) or SGI-110 monotherapy (n = 5; P = 0Á02) (Fig 6B) . Furthermore, CD4 and CD8 splenocytes were evaluated for PD-1 expression. The data demonstrates a significant decrease in PD-1 levels following treatment with SGI-110. However, addition of the vaccine did not further alter PD-1 expression (Fig 6C) . Survival studies demonstrate that animals treated with SGI-110 or the vaccine had improved survival as compared to control animals (P = 0Á001). Consistent with the above findings, combination therapy with the vaccine and SGI-110 extends survival when compared to either therapy alone (Fig 6D) .
Discussion
Immune evasion is a critical aspect of AML disease progression, characterized by the loss of immunogenicity of the AML cell and the creation of an immunosuppressive TME that fosters tolerance and disease growth. The potency of cellular immunotherapy as a uniquely effective therapeutic strategy for AML is highlighted by the observation that alloSCT is curative for a subset of patients due to the graftversus-disease effect mediated by alloreactive lymphocytes (Copelan, 2006) . However, the lack of specificity of this response is associated with significant morbidity due to graft-versus-host disease and relapse (Soiffer, 2008) . A major area of investigation is the development of strategies to induce leukaemia-specific T cell immunity that selectively targets leukaemia cells. We have developed a promising personalized cancer vaccine in which patient-derived AML cells are fused with autologous DCs (Rosenblatt et al, 2016) . Vaccination is associated (A) (B) Fig 3. HMA upregulates the endogenous retroviral (ERV) pathway. MOLM-14 (A) and MV4-11 (B) cells were exposed to decitabine (DAC) at 25 or 50 nmol/L daily for 3 days and analysed for ERV-3 expression using Western blotting (immunoblot, IB) on day 4 of treatment. The results showed significant upregulation of ERV-3 expression following treatment. Due to activation of the ERV pathway, increased IFNß expression was observed with WB analysis.
with a persistent expansion of leukaemia-specific T cells with enhanced expression of IFN-c and protection from relapse. In a phase II clinical trial, vaccination of AML patients following chemotherapy-induced remission resulted in 71% of patients demonstrating remission with nearly 5 years of follow-up despite a median age of 63 years. Despite these promising findings, there is ongoing concern that potency of leukaemia-specific effector cells to mediate durable clinical responses is subject to the immunosuppressive regulation of the TME, which promotes inactivation of tumour-reactive lymphocytes, fostering immune tolerance (Andersen, 2014; Isidori et al, 2014; Schl€ oßer et al, 2014; Armand, 2015; Sharma & Allison, 2015) . Of note, targeting the microenvironment with checkpoint inhibitors alone has been ineffective in AML, probably due to the lack of a significant presence of leukaemia-specific effector cells to activate. As such, the rational pairing of strategies to expand leukaemiaspecific T cells with efforts to effectively target critical factors of the immunosuppressive microenvironment is vital. HMAs demonstrate therapeutic activity against AML and are increasingly recognized as immunomodulators (Srivastava et al, 2014) . Through demethylation, HMAs increase tumour antigen expression by allowing for the expression of genes that are otherwise transcriptionally repressed due to promoter methylation (Almstedt et al, 2010; Srivastava et al, 2014) . Pre-treatment of cancer cells with low-dose HMAs enhances responses to subsequent immune checkpoint antibody therapy, and HMA exposure has been demonstrated to increase the expression of immune-related genes that regulate antigen processing and presentation, IFN signalling, and cytokine production in various tumour models (Juergens et al, 2011; Li et al, 2014) .
In the present study, HMA exposure resulted in enhanced leukaemia-specific immunity in an in-vitro model and an immunocompetent syngeneic AML murine model. The data herein suggests that the increase in leukaemia-specific immunity following HMA therapy is partly due to HMA-mediated reversal of critical immunosuppressive components of the TME and the tumour itself. We demonstrated that HMA exposure results in enhanced antigen presentation, evidenced by increased ligation of MHC1-PR-1 complex to a TCRL antibody mimicking signal one, necessary for T cell activation as well as increased MHCI expression. Increased MHCI expression following HMA therapy has been observed in breast cancer (Luo et al, 2018) . Moreover, culture of patientderived AML cells in the presence of SGI-110 increased TAP2 expression where TAP2 is imperative for antigen presentation and functions to translocate the peptide MHC complex to the cell surface (Leone et al, 2013) .
While other groups have reported that HMAs upregulate T-cell PD-1 expression, we found that the SGI-110 decreases circulating T cell PD-1 expression (Wrangle et al, 2013; Yang et al, 2014; Ørskov et al, 2015) . It has been described that PDCD1 (previously termed PD1) gene transcription is partly regulated through promoter methylation where methylation results in transcriptional silencing of PDCD1 (Youngblood et al, 2011) . In haematological malignancies, 44% of patients (n = 27) treated with a median of 4 HMA cycles showed a loss of DNA methylation in the PDCD1 promoter, and methylation of the promoter was inversely correlated with PDCD1 gene expression in T cells. However, flow cytometry quantified increased PD-1 CD8 T cells expression in only 4 patients (Ørskov et al, 2015) . Treatment of the KG-1 AML cell line with decitabine resulted in demethylation of PD-1 in a dose-dependent manner as observed at concentrations of greater than 1 lM (Yang et al, 2014) . Given these findings, upregulation of PDCD1 following repeated HMA exposure has been explored as a mechanism of possible HMA resistance in haematological malignancies, and clinical trials assessing the combination of HMA with checkpoint blockade are underway. It is likely that PDCD1 T-cell promoter hypermethylation is a dynamic process and demethylation of the PDCD1 promoter requires repeated adequate concentrations of drug exposure, which may be achieved with repeated cycles in patients. It is possible that with one cycle of therapy, as observed in our murine model, the threshold for promoter demethylation was not fully met, and PD-1 expression was therefore not increased. PD-1 T cell surface expression peaked 7 days following HMA therapy.
We also noted decreased MDSC burden following HMA treatment in the murine immunocompetent model, which has not been previously reported in AML. MDSCs are immature myeloid precursors with immunosuppressive capabilities (Gabrilovich & Nagaraj, 2009) . In a breast cancer model, decitabine depleted MDSCs through the induction of apoptosis whereas another model demonstrated the differentiation of MDSCs into mature tumour-derived APCs following HMA therapy (Daurkin et al, 2010; Zhou et al, 2017) .
Recently, an additional pathway by which HMAs elicit immune activation in cancer cells through viral mimicry has been described (Chiappinelli et al, 2015; Roulois et al, 2015) . HMAs activate the ERV defence pathway in tumour cells where ERV genes are remnants of inactive retrovirus DNA that account for about 8% of the human genome. Genes in the HMA with fusion vaccination enhances leukaemia-specific immunity and survival in murine syngeneic AML model. C57BL/6J mice were retro-orbitally inoculated with 100 000 syngeneic TIB-49 acute myeloid leukaemia (AML) cells that were stably transduced with green fluorescent protein (GFP). DC/AML fusion cells were generated. The mice were then treated with either vehicle control, SGI-110 (1 mg/kg) 9 5 days, vaccine alone, or the combination of SGI-110 and fusion vaccine, as shown in the treatment schema (A). The mice were followed for survival and splenocytes were harvested. The cells were then exposed ex-vivo to autologous tumour lysate for 5 days. The cells underwent intracellular flow cytometric analysis for IFN-c expression in both CD4 + and CD8 + T cells (B) and PD-1 expression (C). Mice treated with the combination of SGI-110 plus vaccine had prolonged survival compared to either agent alone (D).
ERV pathway are normally silenced by promoter hypermethylation. Activation of this pathway through demethylation culminates in T-cell activation with inflammatory cytokine production, enhanced T-cell activation and subsequently, cancer cell death (Chiappinelli et al, 2015; Roulois et al, 2015; Strick et al, 2016) . Specifically, activation of this pathway leads to transcription of IFN-stimulated genes that causes IFN-c receptor expression and increased MHCI expression, both leading to T cell activation/IFN-c release and subsequent tumour death. Activation of the ERV pathway by HMAs also results in double-stranded RNA (dsRNA)-elicited IFNb production. In a colon cancer model, HMAs induced the transcription of endogenous dsRNAs activating this IFN response pathway, causing decreased proliferation of colorectal cancerinitiating cells (Roulois et al, 2015) . In the present study, we observed a significant upregulation in ERV-3 and IFNb by Western blotting following HMA exposure in leukaemia cells. Consistent with activation of this pathway, we report increased MHC1 expression on AML blasts following HMA exposure.
We subsequently examined whether the combination of SGI-110 and vaccination could synergistically result in leukaemia cell death through the reversal of tolerance in the TME. Here we demonstrate that fusion vaccination with SGI-110 enhances leukaemia-specific immunity both in-vitro and in our murine model. We did not observe a synergistic decrease in MDSC burden with the combination of vaccine and HMA, suggesting this effect is solely HMA-mediated. Similarly, there was no additive effect on T-cell checkpoint inhibitory expression.
For decades, many groups have utilized dsRNA mimetics, such as poly I:C, to enhance vaccine immunogenicity. Interestingly, it has been shown that dsRNA-elicited IFNb production via these mimetics improves DC functionality (Gatti et al, 2013) . Hence, HMAs theoretically enhance DC functionality through the production of IFNb via ERV pathway activation. This may additionally explain why we observed enhanced leukaemia-specific immunity in our combinatorial fusion plus HMA murine model, augmenting the immunological eradication of AML cells and resulting in a survival benefit.
In conclusion, we have demonstrated that the HMA SGI-110 modulates critical factors contributing to the immunosuppressive milieu in AML resulting in enhanced anti-leukaemic immunity. HMAs markedly enhance antigen presentation and the immunogenicity of AML cells through increased antigen processing and presentation. This effect is mediated in part though the activation of endogenous retroviral sequences and the resultant expression of inflammatory markers, such as IFNß. In addition, SGI-110 augments the immune response to DC/AML vaccination in a murine model resulting in a survival benefit. The combination of a novel personalized fusion vaccine and HMA holds great potential, and a clinical trial using these therapies is planned.
